middle.news
Vitrafy Charts Clear Path to Commercialisation with FY25 Gains and FY26 Launches
8:43am on Tuesday 5th of August, 2025 AEST
•
Healthcare
Read Story
Vitrafy Charts Clear Path to Commercialisation with FY25 Gains and FY26 Launches
8:43am on Tuesday 5th of August, 2025 AEST
Key Points
75% year-over-year sales growth driven by aquaculture and Huon partnerships
Advanced VCU2 cryopreservation hardware design and LifeChain software upgrade underway
Successful Phase 1 blood platelet study with U.S. Military, moving to Phase 2 in FY26
$29.6 million cash and liquid assets with runway through 2027
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Vitrafy Life Sciences (ASX:VFY)
OPEN ARTICLE